Viloxazine: Difference between revisions
From Pharmacopedia
More actions
| [pending revision] | [pending revision] |
Expand Viloxazine with Stahl-sourced detail (with skepticism) |
MDElliottMD (talk | contribs) Tier 1 taxonomy consolidation: removed redundant Category:Norepinephrine Reuptake Inhibitors (canonical already present) |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
| brand = Qelbree | | brand = Qelbree | ||
| classes = Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism, non-stimulant ADHD agent | | classes = Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism, non-stimulant ADHD agent | ||
| mechanism = Selective NET inhibitor (no significant DAT activity | | mechanism = Selective NET inhibitor (no significant DAT activity, distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine. | ||
| uses = ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult) | | uses = ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult) | ||
| starting_dose = Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg. | | starting_dose = Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg. | ||
| Line 13: | Line 13: | ||
| bioavailability = Adequate oral bioavailability with extended-release formulation | | bioavailability = Adequate oral bioavailability with extended-release formulation | ||
| pregnancy = Limited data | | pregnancy = Limited data | ||
| legal = Rx | | legal = Rx, '''not a controlled substance''' (no DEA scheduling) | ||
| intro = '''Viloxazine''' (brand name Qelbree) is an extended-release norepinephrine reuptake inhibitor FDA-approved in 2021 for ADHD in children 6 and older, and in 2022 for adults. Originally developed as an antidepressant in Europe in the 1970s (withdrawn for commercial reasons), it was repurposed for ADHD. Like atomoxetine, viloxazine is a non-stimulant alternative that is '''not a controlled substance'''. However, viloxazine has a more complex pharmacology than atomoxetine | | intro = '''Viloxazine''' (brand name Qelbree) is an extended-release norepinephrine reuptake inhibitor FDA-approved in 2021 for ADHD in children 6 and older, and in 2022 for adults. Originally developed as an antidepressant in Europe in the 1970s (withdrawn for commercial reasons), it was repurposed for ADHD. Like atomoxetine, viloxazine is a non-stimulant alternative that is '''not a controlled substance'''. However, viloxazine has a more complex pharmacology than atomoxetine, beyond pure NET inhibition, it has 5HT1A partial agonism and 5HT2B/5HT7 antagonism, which may underlie faster onset (1-2 weeks vs atomoxetine's 4-6 weeks) and possibly different efficacy. | ||
Useful when stimulants are contraindicated, undesirable, or insufficient. Can be combined with stimulants. | Useful when stimulants are contraindicated, undesirable, or insufficient. Can be combined with stimulants. | ||
| Line 22: | Line 22: | ||
}} | }} | ||
[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]] | [[Category:Norepinephrine Reuptake Inhibitors (NRIs)]] | ||
[[Category:Antidepressants]] | [[Category:Antidepressants]] | ||
[[Category:Non-stimulant ADHD Medicines]] | [[Category:Non-stimulant ADHD Medicines]] | ||